---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130433"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:23:33.377497+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics announces positive phase 3 topline results for elegrobart in active thyroid eye disease

## Summary
- REVEAL-1 met primary endpoint with 54% proptosis responder rate for elegrobart Q4W vs 18% placebo at week 24 (p<0.0001).
- Elegrobart Q8W achieved 63% proptosis responder rate vs 18% placebo at week 24.
- Complete resolution of diplopia in 51% of Q4W patients vs 16% placebo at week 24.
- BLA submission for elegrobart anticipated in Q1 2027; REVEAL-2 top-line data expected Q2 2026.
- Company ended Q4 2025 with $875M cash; veligrotug PDUFA date June 30, 2026.

## SEC filing metadata
- accession: 0001193125-26-130433
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/0001193125-26-130433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130433
- JSON: https://secwatch.observer/filing/0001193125-26-130433.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.